nodes	percent_of_prediction	percent_of_DWPC	metapath
Eszopiclone—CYP2C8—Paclitaxel—ovarian cancer	0.0374	0.249	CbGbCtD
Eszopiclone—CYP3A4—Topotecan—ovarian cancer	0.0306	0.204	CbGbCtD
Eszopiclone—CYP2C9—Paclitaxel—ovarian cancer	0.0261	0.174	CbGbCtD
Eszopiclone—CYP3A4—Vinorelbine—ovarian cancer	0.0216	0.144	CbGbCtD
Eszopiclone—CYP3A4—Paclitaxel—ovarian cancer	0.0151	0.101	CbGbCtD
Eszopiclone—TSPO—oviduct—ovarian cancer	0.0125	0.135	CbGeAlD
Eszopiclone—CYP3A4—Docetaxel—ovarian cancer	0.011	0.0731	CbGbCtD
Eszopiclone—CYP3A4—Doxorubicin—ovarian cancer	0.00816	0.0545	CbGbCtD
Eszopiclone—PTGS1—oviduct—ovarian cancer	0.00694	0.075	CbGeAlD
Eszopiclone—TSPO—myometrium—ovarian cancer	0.00399	0.0431	CbGeAlD
Eszopiclone—TSPO—embryo—ovarian cancer	0.00384	0.0415	CbGeAlD
Eszopiclone—GABRG3—testis—ovarian cancer	0.00381	0.0411	CbGeAlD
Eszopiclone—TSPO—epithelium—ovarian cancer	0.00313	0.0339	CbGeAlD
Eszopiclone—TSPO—uterine cervix—ovarian cancer	0.00311	0.0336	CbGeAlD
Eszopiclone—TSPO—decidua—ovarian cancer	0.00296	0.032	CbGeAlD
Eszopiclone—GABRA5—testis—ovarian cancer	0.00293	0.0316	CbGeAlD
Eszopiclone—TSPO—endometrium—ovarian cancer	0.00281	0.0304	CbGeAlD
Eszopiclone—GABRA3—testis—ovarian cancer	0.00272	0.0294	CbGeAlD
Eszopiclone—TSPO—gonad—ovarian cancer	0.00261	0.0282	CbGeAlD
Eszopiclone—TSPO—uterus—ovarian cancer	0.00259	0.028	CbGeAlD
Eszopiclone—TSPO—female reproductive system—ovarian cancer	0.00233	0.0251	CbGeAlD
Eszopiclone—GABRA2—vagina—ovarian cancer	0.00227	0.0246	CbGeAlD
Eszopiclone—GABRB2—testis—ovarian cancer	0.00222	0.024	CbGeAlD
Eszopiclone—TSPO—bone marrow—ovarian cancer	0.0022	0.0237	CbGeAlD
Eszopiclone—TSPO—female gonad—ovarian cancer	0.00212	0.0229	CbGeAlD
Eszopiclone—TSPO—vagina—ovarian cancer	0.00211	0.0227	CbGeAlD
Eszopiclone—CYP2C8—endometrium—ovarian cancer	0.00193	0.0208	CbGeAlD
Eszopiclone—TSPO—testis—ovarian cancer	0.00188	0.0203	CbGeAlD
Eszopiclone—PTGS1—epithelium—ovarian cancer	0.00174	0.0188	CbGeAlD
Eszopiclone—PTGS1—uterine cervix—ovarian cancer	0.00173	0.0187	CbGeAlD
Eszopiclone—CYP2C8—female reproductive system—ovarian cancer	0.0016	0.0173	CbGeAlD
Eszopiclone—PTGS1—endometrium—ovarian cancer	0.00156	0.0169	CbGeAlD
Eszopiclone—GABRA2—lymph node—ovarian cancer	0.00147	0.0159	CbGeAlD
Eszopiclone—CYP2C8—vagina—ovarian cancer	0.00144	0.0156	CbGeAlD
Eszopiclone—PTGS1—uterus—ovarian cancer	0.00144	0.0156	CbGeAlD
Eszopiclone—CYP2C9—female reproductive system—ovarian cancer	0.00142	0.0153	CbGeAlD
Eszopiclone—TSPO—lymph node—ovarian cancer	0.00136	0.0147	CbGeAlD
Eszopiclone—PTGS1—female reproductive system—ovarian cancer	0.0013	0.014	CbGeAlD
Eszopiclone—CYP2C8—testis—ovarian cancer	0.00129	0.0139	CbGeAlD
Eszopiclone—PTGS1—female gonad—ovarian cancer	0.00118	0.0127	CbGeAlD
Eszopiclone—PTGS1—vagina—ovarian cancer	0.00117	0.0127	CbGeAlD
Eszopiclone—CYP3A4—female reproductive system—ovarian cancer	0.00108	0.0117	CbGeAlD
Eszopiclone—PTGS1—testis—ovarian cancer	0.00105	0.0113	CbGeAlD
Eszopiclone—PTGS1—lymph node—ovarian cancer	0.000758	0.00819	CbGeAlD
Eszopiclone—Myalgia—Paclitaxel—ovarian cancer	0.000636	0.000843	CcSEcCtD
Eszopiclone—Anxiety—Paclitaxel—ovarian cancer	0.000634	0.00084	CcSEcCtD
Eszopiclone—Face oedema—Doxorubicin—ovarian cancer	0.000634	0.00084	CcSEcCtD
Eszopiclone—Nausea—Topotecan—ovarian cancer	0.00063	0.000835	CcSEcCtD
Eszopiclone—Discomfort—Paclitaxel—ovarian cancer	0.000629	0.000833	CcSEcCtD
Eszopiclone—Gastritis—Epirubicin—ovarian cancer	0.000628	0.000832	CcSEcCtD
Eszopiclone—Muscular weakness—Epirubicin—ovarian cancer	0.000626	0.000829	CcSEcCtD
Eszopiclone—Dry mouth—Paclitaxel—ovarian cancer	0.000622	0.000825	CcSEcCtD
Eszopiclone—Mood swings—Doxorubicin—ovarian cancer	0.000622	0.000824	CcSEcCtD
Eszopiclone—Diarrhoea—Vinorelbine—ovarian cancer	0.00062	0.000822	CcSEcCtD
Eszopiclone—Dysgeusia—Docetaxel—ovarian cancer	0.00062	0.000822	CcSEcCtD
Eszopiclone—Ataxia—Doxorubicin—ovarian cancer	0.000617	0.000818	CcSEcCtD
Eszopiclone—Nausea—Melphalan—ovarian cancer	0.000616	0.000817	CcSEcCtD
Eszopiclone—Confusional state—Paclitaxel—ovarian cancer	0.000615	0.000815	CcSEcCtD
Eszopiclone—Asthma—Epirubicin—ovarian cancer	0.000613	0.000813	CcSEcCtD
Eszopiclone—Dysphagia—Epirubicin—ovarian cancer	0.000613	0.000813	CcSEcCtD
Eszopiclone—Influenza—Epirubicin—ovarian cancer	0.000613	0.000813	CcSEcCtD
Eszopiclone—Back pain—Docetaxel—ovarian cancer	0.000613	0.000812	CcSEcCtD
Eszopiclone—Dehydration—Doxorubicin—ovarian cancer	0.00061	0.000809	CcSEcCtD
Eszopiclone—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00061	0.000808	CcSEcCtD
Eszopiclone—Muscle spasms—Docetaxel—ovarian cancer	0.000609	0.000807	CcSEcCtD
Eszopiclone—Infection—Paclitaxel—ovarian cancer	0.000606	0.000803	CcSEcCtD
Eszopiclone—Dry skin—Doxorubicin—ovarian cancer	0.000602	0.000798	CcSEcCtD
Eszopiclone—Dizziness—Vinorelbine—ovarian cancer	0.0006	0.000795	CcSEcCtD
Eszopiclone—Hypokalaemia—Doxorubicin—ovarian cancer	0.000597	0.000792	CcSEcCtD
Eszopiclone—Tachycardia—Paclitaxel—ovarian cancer	0.000595	0.000789	CcSEcCtD
Eszopiclone—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000591	0.000783	CcSEcCtD
Eszopiclone—Bronchitis—Epirubicin—ovarian cancer	0.00059	0.000782	CcSEcCtD
Eszopiclone—Hyperhidrosis—Paclitaxel—ovarian cancer	0.00059	0.000781	CcSEcCtD
Eszopiclone—Anaemia—Docetaxel—ovarian cancer	0.000585	0.000776	CcSEcCtD
Eszopiclone—Anorexia—Paclitaxel—ovarian cancer	0.000581	0.000771	CcSEcCtD
Eszopiclone—Gastritis—Doxorubicin—ovarian cancer	0.000581	0.00077	CcSEcCtD
Eszopiclone—Muscular weakness—Doxorubicin—ovarian cancer	0.000579	0.000767	CcSEcCtD
Eszopiclone—Vomiting—Vinorelbine—ovarian cancer	0.000576	0.000764	CcSEcCtD
Eszopiclone—Dysuria—Epirubicin—ovarian cancer	0.000573	0.00076	CcSEcCtD
Eszopiclone—Rash—Vinorelbine—ovarian cancer	0.000572	0.000758	CcSEcCtD
Eszopiclone—Dermatitis—Vinorelbine—ovarian cancer	0.000571	0.000757	CcSEcCtD
Eszopiclone—Headache—Vinorelbine—ovarian cancer	0.000568	0.000753	CcSEcCtD
Eszopiclone—Dysphagia—Doxorubicin—ovarian cancer	0.000567	0.000752	CcSEcCtD
Eszopiclone—Asthma—Doxorubicin—ovarian cancer	0.000567	0.000752	CcSEcCtD
Eszopiclone—Influenza—Doxorubicin—ovarian cancer	0.000567	0.000752	CcSEcCtD
Eszopiclone—Pollakiuria—Epirubicin—ovarian cancer	0.000566	0.000751	CcSEcCtD
Eszopiclone—Palpitations—Docetaxel—ovarian cancer	0.00056	0.000742	CcSEcCtD
Eszopiclone—Photosensitivity reaction—Epirubicin—ovarian cancer	0.00056	0.000742	CcSEcCtD
Eszopiclone—Weight increased—Epirubicin—ovarian cancer	0.000558	0.00074	CcSEcCtD
Eszopiclone—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000556	0.000737	CcSEcCtD
Eszopiclone—Weight decreased—Epirubicin—ovarian cancer	0.000555	0.000735	CcSEcCtD
Eszopiclone—Insomnia—Paclitaxel—ovarian cancer	0.000552	0.000731	CcSEcCtD
Eszopiclone—Convulsion—Docetaxel—ovarian cancer	0.000549	0.000727	CcSEcCtD
Eszopiclone—Paraesthesia—Paclitaxel—ovarian cancer	0.000548	0.000726	CcSEcCtD
Eszopiclone—Hypertension—Docetaxel—ovarian cancer	0.000547	0.000725	CcSEcCtD
Eszopiclone—Drowsiness—Epirubicin—ovarian cancer	0.000547	0.000725	CcSEcCtD
Eszopiclone—Bronchitis—Doxorubicin—ovarian cancer	0.000546	0.000723	CcSEcCtD
Eszopiclone—Dyspnoea—Paclitaxel—ovarian cancer	0.000544	0.000721	CcSEcCtD
Eszopiclone—Somnolence—Paclitaxel—ovarian cancer	0.000542	0.000719	CcSEcCtD
Eszopiclone—Chest pain—Docetaxel—ovarian cancer	0.000539	0.000715	CcSEcCtD
Eszopiclone—Myalgia—Docetaxel—ovarian cancer	0.000539	0.000715	CcSEcCtD
Eszopiclone—Nausea—Vinorelbine—ovarian cancer	0.000539	0.000714	CcSEcCtD
Eszopiclone—Dyspepsia—Paclitaxel—ovarian cancer	0.000537	0.000712	CcSEcCtD
Eszopiclone—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000536	0.00071	CcSEcCtD
Eszopiclone—Stomatitis—Epirubicin—ovarian cancer	0.000533	0.000706	CcSEcCtD
Eszopiclone—Conjunctivitis—Epirubicin—ovarian cancer	0.000531	0.000704	CcSEcCtD
Eszopiclone—Urinary tract infection—Epirubicin—ovarian cancer	0.000531	0.000704	CcSEcCtD
Eszopiclone—Dysuria—Doxorubicin—ovarian cancer	0.00053	0.000703	CcSEcCtD
Eszopiclone—Decreased appetite—Paclitaxel—ovarian cancer	0.00053	0.000703	CcSEcCtD
Eszopiclone—Dry mouth—Docetaxel—ovarian cancer	0.000527	0.000699	CcSEcCtD
Eszopiclone—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000527	0.000698	CcSEcCtD
Eszopiclone—Fatigue—Paclitaxel—ovarian cancer	0.000526	0.000697	CcSEcCtD
Eszopiclone—Sweating—Epirubicin—ovarian cancer	0.000524	0.000695	CcSEcCtD
Eszopiclone—Pollakiuria—Doxorubicin—ovarian cancer	0.000524	0.000695	CcSEcCtD
Eszopiclone—Pain—Paclitaxel—ovarian cancer	0.000522	0.000691	CcSEcCtD
Eszopiclone—Constipation—Paclitaxel—ovarian cancer	0.000522	0.000691	CcSEcCtD
Eszopiclone—Haematuria—Epirubicin—ovarian cancer	0.000521	0.000691	CcSEcCtD
Eszopiclone—Confusional state—Docetaxel—ovarian cancer	0.000521	0.000691	CcSEcCtD
Eszopiclone—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000518	0.000686	CcSEcCtD
Eszopiclone—Anaphylactic shock—Docetaxel—ovarian cancer	0.000517	0.000685	CcSEcCtD
Eszopiclone—Weight increased—Doxorubicin—ovarian cancer	0.000516	0.000684	CcSEcCtD
Eszopiclone—Epistaxis—Epirubicin—ovarian cancer	0.000516	0.000683	CcSEcCtD
Eszopiclone—Infection—Docetaxel—ovarian cancer	0.000514	0.000681	CcSEcCtD
Eszopiclone—Weight decreased—Doxorubicin—ovarian cancer	0.000513	0.00068	CcSEcCtD
Eszopiclone—Drowsiness—Doxorubicin—ovarian cancer	0.000506	0.00067	CcSEcCtD
Eszopiclone—Tachycardia—Docetaxel—ovarian cancer	0.000504	0.000669	CcSEcCtD
Eszopiclone—Feeling abnormal—Paclitaxel—ovarian cancer	0.000503	0.000666	CcSEcCtD
Eszopiclone—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000499	0.000661	CcSEcCtD
Eszopiclone—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000496	0.000657	CcSEcCtD
Eszopiclone—Stomatitis—Doxorubicin—ovarian cancer	0.000493	0.000654	CcSEcCtD
Eszopiclone—Anorexia—Docetaxel—ovarian cancer	0.000493	0.000653	CcSEcCtD
Eszopiclone—Rhinitis—Epirubicin—ovarian cancer	0.000492	0.000652	CcSEcCtD
Eszopiclone—Conjunctivitis—Doxorubicin—ovarian cancer	0.000492	0.000652	CcSEcCtD
Eszopiclone—Urinary tract infection—Doxorubicin—ovarian cancer	0.000492	0.000652	CcSEcCtD
Eszopiclone—Hepatitis—Epirubicin—ovarian cancer	0.000491	0.000651	CcSEcCtD
Eszopiclone—Hypoaesthesia—Epirubicin—ovarian cancer	0.000488	0.000647	CcSEcCtD
Eszopiclone—Pharyngitis—Epirubicin—ovarian cancer	0.000487	0.000646	CcSEcCtD
Eszopiclone—Sweating—Doxorubicin—ovarian cancer	0.000485	0.000643	CcSEcCtD
Eszopiclone—Urticaria—Paclitaxel—ovarian cancer	0.000484	0.000642	CcSEcCtD
Eszopiclone—Oedema peripheral—Epirubicin—ovarian cancer	0.000483	0.000641	CcSEcCtD
Eszopiclone—Haematuria—Doxorubicin—ovarian cancer	0.000482	0.000639	CcSEcCtD
Eszopiclone—Abdominal pain—Paclitaxel—ovarian cancer	0.000482	0.000639	CcSEcCtD
Eszopiclone—Body temperature increased—Paclitaxel—ovarian cancer	0.000482	0.000639	CcSEcCtD
Eszopiclone—Epistaxis—Doxorubicin—ovarian cancer	0.000477	0.000632	CcSEcCtD
Eszopiclone—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000471	0.000624	CcSEcCtD
Eszopiclone—Insomnia—Docetaxel—ovarian cancer	0.000468	0.00062	CcSEcCtD
Eszopiclone—Paraesthesia—Docetaxel—ovarian cancer	0.000464	0.000615	CcSEcCtD
Eszopiclone—Erythema multiforme—Epirubicin—ovarian cancer	0.000464	0.000615	CcSEcCtD
Eszopiclone—Dyspnoea—Docetaxel—ovarian cancer	0.000461	0.000611	CcSEcCtD
Eszopiclone—Somnolence—Docetaxel—ovarian cancer	0.00046	0.000609	CcSEcCtD
Eszopiclone—Tinnitus—Epirubicin—ovarian cancer	0.000458	0.000607	CcSEcCtD
Eszopiclone—Rhinitis—Doxorubicin—ovarian cancer	0.000455	0.000603	CcSEcCtD
Eszopiclone—Dyspepsia—Docetaxel—ovarian cancer	0.000455	0.000603	CcSEcCtD
Eszopiclone—Hepatitis—Doxorubicin—ovarian cancer	0.000454	0.000602	CcSEcCtD
Eszopiclone—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000452	0.000599	CcSEcCtD
Eszopiclone—Pharyngitis—Doxorubicin—ovarian cancer	0.000451	0.000597	CcSEcCtD
Eszopiclone—Decreased appetite—Docetaxel—ovarian cancer	0.000449	0.000596	CcSEcCtD
Eszopiclone—Hypersensitivity—Paclitaxel—ovarian cancer	0.000449	0.000596	CcSEcCtD
Eszopiclone—Oedema peripheral—Doxorubicin—ovarian cancer	0.000447	0.000593	CcSEcCtD
Eszopiclone—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000446	0.000592	CcSEcCtD
Eszopiclone—Fatigue—Docetaxel—ovarian cancer	0.000446	0.000591	CcSEcCtD
Eszopiclone—Constipation—Docetaxel—ovarian cancer	0.000442	0.000586	CcSEcCtD
Eszopiclone—Pain—Docetaxel—ovarian cancer	0.000442	0.000586	CcSEcCtD
Eszopiclone—Chills—Epirubicin—ovarian cancer	0.00044	0.000584	CcSEcCtD
Eszopiclone—Asthenia—Paclitaxel—ovarian cancer	0.000438	0.00058	CcSEcCtD
Eszopiclone—Alopecia—Epirubicin—ovarian cancer	0.000434	0.000575	CcSEcCtD
Eszopiclone—Pruritus—Paclitaxel—ovarian cancer	0.000431	0.000572	CcSEcCtD
Eszopiclone—Erythema multiforme—Doxorubicin—ovarian cancer	0.000429	0.000569	CcSEcCtD
Eszopiclone—Feeling abnormal—Docetaxel—ovarian cancer	0.000426	0.000565	CcSEcCtD
Eszopiclone—Tinnitus—Doxorubicin—ovarian cancer	0.000423	0.000561	CcSEcCtD
Eszopiclone—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000423	0.00056	CcSEcCtD
Eszopiclone—Tension—Epirubicin—ovarian cancer	0.000419	0.000556	CcSEcCtD
Eszopiclone—Dysgeusia—Epirubicin—ovarian cancer	0.000418	0.000555	CcSEcCtD
Eszopiclone—Diarrhoea—Paclitaxel—ovarian cancer	0.000417	0.000553	CcSEcCtD
Eszopiclone—Nervousness—Epirubicin—ovarian cancer	0.000415	0.00055	CcSEcCtD
Eszopiclone—Back pain—Epirubicin—ovarian cancer	0.000413	0.000548	CcSEcCtD
Eszopiclone—Muscle spasms—Epirubicin—ovarian cancer	0.000411	0.000544	CcSEcCtD
Eszopiclone—Abdominal pain—Docetaxel—ovarian cancer	0.000409	0.000542	CcSEcCtD
Eszopiclone—Body temperature increased—Docetaxel—ovarian cancer	0.000409	0.000542	CcSEcCtD
Eszopiclone—Chills—Doxorubicin—ovarian cancer	0.000407	0.00054	CcSEcCtD
Eszopiclone—Dizziness—Paclitaxel—ovarian cancer	0.000403	0.000535	CcSEcCtD
Eszopiclone—Vision blurred—Epirubicin—ovarian cancer	0.000403	0.000534	CcSEcCtD
Eszopiclone—Alopecia—Doxorubicin—ovarian cancer	0.000401	0.000532	CcSEcCtD
Eszopiclone—Ill-defined disorder—Epirubicin—ovarian cancer	0.000396	0.000525	CcSEcCtD
Eszopiclone—Anaemia—Epirubicin—ovarian cancer	0.000395	0.000523	CcSEcCtD
Eszopiclone—Agitation—Epirubicin—ovarian cancer	0.000393	0.00052	CcSEcCtD
Eszopiclone—Tension—Doxorubicin—ovarian cancer	0.000388	0.000514	CcSEcCtD
Eszopiclone—Vomiting—Paclitaxel—ovarian cancer	0.000388	0.000514	CcSEcCtD
Eszopiclone—Dysgeusia—Doxorubicin—ovarian cancer	0.000387	0.000513	CcSEcCtD
Eszopiclone—Malaise—Epirubicin—ovarian cancer	0.000385	0.000511	CcSEcCtD
Eszopiclone—Rash—Paclitaxel—ovarian cancer	0.000385	0.00051	CcSEcCtD
Eszopiclone—Dermatitis—Paclitaxel—ovarian cancer	0.000384	0.000509	CcSEcCtD
Eszopiclone—Nervousness—Doxorubicin—ovarian cancer	0.000384	0.000509	CcSEcCtD
Eszopiclone—Vertigo—Epirubicin—ovarian cancer	0.000384	0.000509	CcSEcCtD
Eszopiclone—Back pain—Doxorubicin—ovarian cancer	0.000382	0.000507	CcSEcCtD
Eszopiclone—Headache—Paclitaxel—ovarian cancer	0.000382	0.000506	CcSEcCtD
Eszopiclone—Hypersensitivity—Docetaxel—ovarian cancer	0.000381	0.000505	CcSEcCtD
Eszopiclone—Muscle spasms—Doxorubicin—ovarian cancer	0.00038	0.000504	CcSEcCtD
Eszopiclone—Palpitations—Epirubicin—ovarian cancer	0.000378	0.0005	CcSEcCtD
Eszopiclone—Vision blurred—Doxorubicin—ovarian cancer	0.000373	0.000494	CcSEcCtD
Eszopiclone—Asthenia—Docetaxel—ovarian cancer	0.000371	0.000492	CcSEcCtD
Eszopiclone—Convulsion—Epirubicin—ovarian cancer	0.00037	0.000491	CcSEcCtD
Eszopiclone—Hypertension—Epirubicin—ovarian cancer	0.000369	0.000489	CcSEcCtD
Eszopiclone—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000367	0.000486	CcSEcCtD
Eszopiclone—Pruritus—Docetaxel—ovarian cancer	0.000366	0.000485	CcSEcCtD
Eszopiclone—Anaemia—Doxorubicin—ovarian cancer	0.000365	0.000484	CcSEcCtD
Eszopiclone—Myalgia—Epirubicin—ovarian cancer	0.000364	0.000482	CcSEcCtD
Eszopiclone—Chest pain—Epirubicin—ovarian cancer	0.000364	0.000482	CcSEcCtD
Eszopiclone—Agitation—Doxorubicin—ovarian cancer	0.000363	0.000482	CcSEcCtD
Eszopiclone—Anxiety—Epirubicin—ovarian cancer	0.000362	0.00048	CcSEcCtD
Eszopiclone—Nausea—Paclitaxel—ovarian cancer	0.000362	0.00048	CcSEcCtD
Eszopiclone—Discomfort—Epirubicin—ovarian cancer	0.000359	0.000476	CcSEcCtD
Eszopiclone—Malaise—Doxorubicin—ovarian cancer	0.000356	0.000473	CcSEcCtD
Eszopiclone—Dry mouth—Epirubicin—ovarian cancer	0.000356	0.000472	CcSEcCtD
Eszopiclone—Vertigo—Doxorubicin—ovarian cancer	0.000355	0.000471	CcSEcCtD
Eszopiclone—Diarrhoea—Docetaxel—ovarian cancer	0.000354	0.000469	CcSEcCtD
Eszopiclone—Confusional state—Epirubicin—ovarian cancer	0.000352	0.000466	CcSEcCtD
Eszopiclone—Palpitations—Doxorubicin—ovarian cancer	0.000349	0.000463	CcSEcCtD
Eszopiclone—Anaphylactic shock—Epirubicin—ovarian cancer	0.000349	0.000462	CcSEcCtD
Eszopiclone—Infection—Epirubicin—ovarian cancer	0.000346	0.000459	CcSEcCtD
Eszopiclone—Convulsion—Doxorubicin—ovarian cancer	0.000342	0.000454	CcSEcCtD
Eszopiclone—Dizziness—Docetaxel—ovarian cancer	0.000342	0.000453	CcSEcCtD
Eszopiclone—Hypertension—Doxorubicin—ovarian cancer	0.000341	0.000452	CcSEcCtD
Eszopiclone—Tachycardia—Epirubicin—ovarian cancer	0.00034	0.000451	CcSEcCtD
Eszopiclone—Hyperhidrosis—Epirubicin—ovarian cancer	0.000337	0.000447	CcSEcCtD
Eszopiclone—Myalgia—Doxorubicin—ovarian cancer	0.000337	0.000446	CcSEcCtD
Eszopiclone—Chest pain—Doxorubicin—ovarian cancer	0.000337	0.000446	CcSEcCtD
Eszopiclone—Anxiety—Doxorubicin—ovarian cancer	0.000335	0.000445	CcSEcCtD
Eszopiclone—Discomfort—Doxorubicin—ovarian cancer	0.000332	0.000441	CcSEcCtD
Eszopiclone—Anorexia—Epirubicin—ovarian cancer	0.000332	0.000441	CcSEcCtD
Eszopiclone—Dry mouth—Doxorubicin—ovarian cancer	0.000329	0.000436	CcSEcCtD
Eszopiclone—Vomiting—Docetaxel—ovarian cancer	0.000329	0.000436	CcSEcCtD
Eszopiclone—Rash—Docetaxel—ovarian cancer	0.000326	0.000432	CcSEcCtD
Eszopiclone—Dermatitis—Docetaxel—ovarian cancer	0.000326	0.000432	CcSEcCtD
Eszopiclone—Confusional state—Doxorubicin—ovarian cancer	0.000325	0.000431	CcSEcCtD
Eszopiclone—Headache—Docetaxel—ovarian cancer	0.000324	0.000429	CcSEcCtD
Eszopiclone—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000323	0.000428	CcSEcCtD
Eszopiclone—Infection—Doxorubicin—ovarian cancer	0.00032	0.000425	CcSEcCtD
Eszopiclone—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000318	0.000421	CcSEcCtD
Eszopiclone—Insomnia—Epirubicin—ovarian cancer	0.000315	0.000418	CcSEcCtD
Eszopiclone—Tachycardia—Doxorubicin—ovarian cancer	0.000315	0.000417	CcSEcCtD
Eszopiclone—Paraesthesia—Epirubicin—ovarian cancer	0.000313	0.000415	CcSEcCtD
Eszopiclone—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000312	0.000413	CcSEcCtD
Eszopiclone—Dyspnoea—Epirubicin—ovarian cancer	0.000311	0.000412	CcSEcCtD
Eszopiclone—Somnolence—Epirubicin—ovarian cancer	0.00031	0.000411	CcSEcCtD
Eszopiclone—Anorexia—Doxorubicin—ovarian cancer	0.000308	0.000408	CcSEcCtD
Eszopiclone—Nausea—Docetaxel—ovarian cancer	0.000307	0.000407	CcSEcCtD
Eszopiclone—Dyspepsia—Epirubicin—ovarian cancer	0.000307	0.000407	CcSEcCtD
Eszopiclone—Decreased appetite—Epirubicin—ovarian cancer	0.000303	0.000402	CcSEcCtD
Eszopiclone—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000301	0.000399	CcSEcCtD
Eszopiclone—Fatigue—Epirubicin—ovarian cancer	0.000301	0.000398	CcSEcCtD
Eszopiclone—Constipation—Epirubicin—ovarian cancer	0.000298	0.000395	CcSEcCtD
Eszopiclone—Pain—Epirubicin—ovarian cancer	0.000298	0.000395	CcSEcCtD
Eszopiclone—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000294	0.00039	CcSEcCtD
Eszopiclone—Insomnia—Doxorubicin—ovarian cancer	0.000292	0.000387	CcSEcCtD
Eszopiclone—Paraesthesia—Doxorubicin—ovarian cancer	0.00029	0.000384	CcSEcCtD
Eszopiclone—Dyspnoea—Doxorubicin—ovarian cancer	0.000288	0.000381	CcSEcCtD
Eszopiclone—Feeling abnormal—Epirubicin—ovarian cancer	0.000287	0.000381	CcSEcCtD
Eszopiclone—Somnolence—Doxorubicin—ovarian cancer	0.000287	0.00038	CcSEcCtD
Eszopiclone—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000285	0.000378	CcSEcCtD
Eszopiclone—Dyspepsia—Doxorubicin—ovarian cancer	0.000284	0.000376	CcSEcCtD
Eszopiclone—Decreased appetite—Doxorubicin—ovarian cancer	0.00028	0.000372	CcSEcCtD
Eszopiclone—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000279	0.000369	CcSEcCtD
Eszopiclone—Fatigue—Doxorubicin—ovarian cancer	0.000278	0.000369	CcSEcCtD
Eszopiclone—Urticaria—Epirubicin—ovarian cancer	0.000277	0.000367	CcSEcCtD
Eszopiclone—Pain—Doxorubicin—ovarian cancer	0.000276	0.000366	CcSEcCtD
Eszopiclone—Constipation—Doxorubicin—ovarian cancer	0.000276	0.000366	CcSEcCtD
Eszopiclone—Abdominal pain—Epirubicin—ovarian cancer	0.000276	0.000365	CcSEcCtD
Eszopiclone—Body temperature increased—Epirubicin—ovarian cancer	0.000276	0.000365	CcSEcCtD
Eszopiclone—Feeling abnormal—Doxorubicin—ovarian cancer	0.000266	0.000352	CcSEcCtD
Eszopiclone—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000264	0.00035	CcSEcCtD
Eszopiclone—Hypersensitivity—Epirubicin—ovarian cancer	0.000257	0.000341	CcSEcCtD
Eszopiclone—Urticaria—Doxorubicin—ovarian cancer	0.000256	0.00034	CcSEcCtD
Eszopiclone—Body temperature increased—Doxorubicin—ovarian cancer	0.000255	0.000338	CcSEcCtD
Eszopiclone—Abdominal pain—Doxorubicin—ovarian cancer	0.000255	0.000338	CcSEcCtD
Eszopiclone—Asthenia—Epirubicin—ovarian cancer	0.00025	0.000332	CcSEcCtD
Eszopiclone—Pruritus—Epirubicin—ovarian cancer	0.000247	0.000327	CcSEcCtD
Eszopiclone—Diarrhoea—Epirubicin—ovarian cancer	0.000239	0.000316	CcSEcCtD
Eszopiclone—Hypersensitivity—Doxorubicin—ovarian cancer	0.000238	0.000315	CcSEcCtD
Eszopiclone—Asthenia—Doxorubicin—ovarian cancer	0.000231	0.000307	CcSEcCtD
Eszopiclone—Dizziness—Epirubicin—ovarian cancer	0.000231	0.000306	CcSEcCtD
Eszopiclone—Pruritus—Doxorubicin—ovarian cancer	0.000228	0.000303	CcSEcCtD
Eszopiclone—Vomiting—Epirubicin—ovarian cancer	0.000222	0.000294	CcSEcCtD
Eszopiclone—Diarrhoea—Doxorubicin—ovarian cancer	0.000221	0.000293	CcSEcCtD
Eszopiclone—Rash—Epirubicin—ovarian cancer	0.00022	0.000291	CcSEcCtD
Eszopiclone—Dermatitis—Epirubicin—ovarian cancer	0.00022	0.000291	CcSEcCtD
Eszopiclone—Headache—Epirubicin—ovarian cancer	0.000218	0.00029	CcSEcCtD
Eszopiclone—Dizziness—Doxorubicin—ovarian cancer	0.000213	0.000283	CcSEcCtD
Eszopiclone—Nausea—Epirubicin—ovarian cancer	0.000207	0.000275	CcSEcCtD
Eszopiclone—Vomiting—Doxorubicin—ovarian cancer	0.000205	0.000272	CcSEcCtD
Eszopiclone—Rash—Doxorubicin—ovarian cancer	0.000203	0.00027	CcSEcCtD
Eszopiclone—Dermatitis—Doxorubicin—ovarian cancer	0.000203	0.000269	CcSEcCtD
Eszopiclone—Headache—Doxorubicin—ovarian cancer	0.000202	0.000268	CcSEcCtD
Eszopiclone—Nausea—Doxorubicin—ovarian cancer	0.000192	0.000254	CcSEcCtD
Eszopiclone—GABRG3—Neuronal System—NSF—ovarian cancer	2.88e-05	0.00903	CbGpPWpGaD
Eszopiclone—PTGS1—Overview of nanoparticle effects—CXCL8—ovarian cancer	2.75e-05	0.0086	CbGpPWpGaD
Eszopiclone—GABRA4—Neuronal System—NSF—ovarian cancer	2.65e-05	0.00831	CbGpPWpGaD
Eszopiclone—GABRA1—Ion channel transport—ATP7B—ovarian cancer	2.6e-05	0.00814	CbGpPWpGaD
Eszopiclone—GABRA1—Transmission across Chemical Synapses—NSF—ovarian cancer	2.53e-05	0.00793	CbGpPWpGaD
Eszopiclone—GABRB2—Neuronal System—NSF—ovarian cancer	2.43e-05	0.0076	CbGpPWpGaD
Eszopiclone—GABRA5—Neuronal System—NSF—ovarian cancer	2.36e-05	0.00739	CbGpPWpGaD
Eszopiclone—GABRA3—Neuronal System—NSF—ovarian cancer	2.31e-05	0.00725	CbGpPWpGaD
Eszopiclone—GABRA2—Neuronal System—NSF—ovarian cancer	2.27e-05	0.00713	CbGpPWpGaD
Eszopiclone—CYP3A4—Estrogen metabolism—CYP1B1—ovarian cancer	2.27e-05	0.00713	CbGpPWpGaD
Eszopiclone—GABRG2—Neuronal System—NSF—ovarian cancer	2.22e-05	0.00696	CbGpPWpGaD
Eszopiclone—PTGS1—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	2.03e-05	0.00636	CbGpPWpGaD
Eszopiclone—CYP3A4—Tamoxifen metabolism—CYP1B1—ovarian cancer	2.01e-05	0.0063	CbGpPWpGaD
Eszopiclone—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—ovarian cancer	1.96e-05	0.00614	CbGpPWpGaD
Eszopiclone—GABRA1—Neuronal System—NSF—ovarian cancer	1.94e-05	0.00608	CbGpPWpGaD
Eszopiclone—CYP2C8—Arachidonic acid metabolism—CYP1B1—ovarian cancer	1.87e-05	0.00586	CbGpPWpGaD
Eszopiclone—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	1.79e-05	0.00562	CbGpPWpGaD
Eszopiclone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	1.71e-05	0.00535	CbGpPWpGaD
Eszopiclone—CYP3A4—Irinotecan Pathway—APC—ovarian cancer	1.65e-05	0.00517	CbGpPWpGaD
Eszopiclone—PTGS1—Selenium Micronutrient Network—SOD1—ovarian cancer	1.64e-05	0.00515	CbGpPWpGaD
Eszopiclone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	1.62e-05	0.00507	CbGpPWpGaD
Eszopiclone—CYP2C8—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	1.6e-05	0.005	CbGpPWpGaD
Eszopiclone—PTGS1—Overview of nanoparticle effects—IL6—ovarian cancer	1.54e-05	0.00483	CbGpPWpGaD
Eszopiclone—CYP2C9—Arachidonic acid metabolism—CYP1B1—ovarian cancer	1.52e-05	0.00477	CbGpPWpGaD
Eszopiclone—PTGS1—Selenium Micronutrient Network—SOD2—ovarian cancer	1.48e-05	0.00463	CbGpPWpGaD
Eszopiclone—GABRG3—Transmembrane transport of small molecules—AQP3—ovarian cancer	1.4e-05	0.00439	CbGpPWpGaD
Eszopiclone—GABRG3—Transmembrane transport of small molecules—ATP7B—ovarian cancer	1.34e-05	0.00421	CbGpPWpGaD
Eszopiclone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	1.32e-05	0.00412	CbGpPWpGaD
Eszopiclone—CYP2C8—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	1.31e-05	0.00411	CbGpPWpGaD
Eszopiclone—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	1.3e-05	0.00407	CbGpPWpGaD
Eszopiclone—GABRA4—Transmembrane transport of small molecules—AQP3—ovarian cancer	1.29e-05	0.00404	CbGpPWpGaD
Eszopiclone—GABRA4—Transmembrane transport of small molecules—ATP7B—ovarian cancer	1.24e-05	0.00388	CbGpPWpGaD
Eszopiclone—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	1.18e-05	0.0037	CbGpPWpGaD
Eszopiclone—GABRB2—Transmembrane transport of small molecules—AQP3—ovarian cancer	1.18e-05	0.0037	CbGpPWpGaD
Eszopiclone—GABRA5—Transmembrane transport of small molecules—AQP3—ovarian cancer	1.15e-05	0.00359	CbGpPWpGaD
Eszopiclone—GABRB2—Transmembrane transport of small molecules—ATP7B—ovarian cancer	1.13e-05	0.00355	CbGpPWpGaD
Eszopiclone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	1.13e-05	0.00353	CbGpPWpGaD
Eszopiclone—GABRA3—Transmembrane transport of small molecules—AQP3—ovarian cancer	1.13e-05	0.00353	CbGpPWpGaD
Eszopiclone—GABRA2—Transmembrane transport of small molecules—AQP3—ovarian cancer	1.11e-05	0.00347	CbGpPWpGaD
Eszopiclone—GABRA5—Transmembrane transport of small molecules—ATP7B—ovarian cancer	1.1e-05	0.00344	CbGpPWpGaD
Eszopiclone—GABRA3—Transmembrane transport of small molecules—ATP7B—ovarian cancer	1.08e-05	0.00338	CbGpPWpGaD
Eszopiclone—GABRG2—Transmembrane transport of small molecules—AQP3—ovarian cancer	1.08e-05	0.00338	CbGpPWpGaD
Eszopiclone—PTGS1—Biological oxidations—CYP1B1—ovarian cancer	1.08e-05	0.00338	CbGpPWpGaD
Eszopiclone—CYP3A4—Tryptophan metabolism—CYP1B1—ovarian cancer	1.07e-05	0.00336	CbGpPWpGaD
Eszopiclone—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	1.07e-05	0.00334	CbGpPWpGaD
Eszopiclone—GABRG3—Transmembrane transport of small molecules—TUBB3—ovarian cancer	1.06e-05	0.00333	CbGpPWpGaD
Eszopiclone—GABRA2—Transmembrane transport of small molecules—ATP7B—ovarian cancer	1.06e-05	0.00332	CbGpPWpGaD
Eszopiclone—GABRG2—Transmembrane transport of small molecules—ATP7B—ovarian cancer	1.03e-05	0.00324	CbGpPWpGaD
Eszopiclone—GABRA4—Transmembrane transport of small molecules—TUBB3—ovarian cancer	9.78e-06	0.00306	CbGpPWpGaD
Eszopiclone—GABRA1—Transmembrane transport of small molecules—AQP3—ovarian cancer	9.43e-06	0.00296	CbGpPWpGaD
Eszopiclone—GABRA1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	9.04e-06	0.00283	CbGpPWpGaD
Eszopiclone—GABRB2—Transmembrane transport of small molecules—TUBB3—ovarian cancer	8.94e-06	0.0028	CbGpPWpGaD
Eszopiclone—GABRA5—Transmembrane transport of small molecules—TUBB3—ovarian cancer	8.69e-06	0.00272	CbGpPWpGaD
Eszopiclone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	8.68e-06	0.00272	CbGpPWpGaD
Eszopiclone—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	8.56e-06	0.00268	CbGpPWpGaD
Eszopiclone—GABRA3—Transmembrane transport of small molecules—TUBB3—ovarian cancer	8.53e-06	0.00267	CbGpPWpGaD
Eszopiclone—GABRA2—Transmembrane transport of small molecules—TUBB3—ovarian cancer	8.38e-06	0.00263	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	8.31e-06	0.00261	CbGpPWpGaD
Eszopiclone—GABRG2—Transmembrane transport of small molecules—TUBB3—ovarian cancer	8.18e-06	0.00256	CbGpPWpGaD
Eszopiclone—GABRA1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	7.15e-06	0.00224	CbGpPWpGaD
Eszopiclone—GABRG3—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	7.09e-06	0.00222	CbGpPWpGaD
Eszopiclone—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	7.04e-06	0.00221	CbGpPWpGaD
Eszopiclone—CYP2C8—Biological oxidations—CYP1B1—ovarian cancer	6.96e-06	0.00218	CbGpPWpGaD
Eszopiclone—CYP2C8—Metapathway biotransformation—CYP1B1—ovarian cancer	6.87e-06	0.00215	CbGpPWpGaD
Eszopiclone—GABRG3—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	6.84e-06	0.00215	CbGpPWpGaD
Eszopiclone—GABRG3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	6.77e-06	0.00212	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—NME2—ovarian cancer	6.57e-06	0.00206	CbGpPWpGaD
Eszopiclone—GABRA4—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	6.52e-06	0.00204	CbGpPWpGaD
Eszopiclone—GABRA4—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	6.3e-06	0.00197	CbGpPWpGaD
Eszopiclone—GABRA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	6.23e-06	0.00195	CbGpPWpGaD
Eszopiclone—GABRB2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	5.97e-06	0.00187	CbGpPWpGaD
Eszopiclone—GABRA5—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	5.8e-06	0.00182	CbGpPWpGaD
Eszopiclone—GABRB2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	5.76e-06	0.00181	CbGpPWpGaD
Eszopiclone—GABRA1—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	5.72e-06	0.00179	CbGpPWpGaD
Eszopiclone—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	5.7e-06	0.00179	CbGpPWpGaD
Eszopiclone—GABRA3—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	5.69e-06	0.00178	CbGpPWpGaD
Eszopiclone—CYP2C9—Biological oxidations—CYP1B1—ovarian cancer	5.67e-06	0.00178	CbGpPWpGaD
Eszopiclone—GABRA5—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	5.6e-06	0.00175	CbGpPWpGaD
Eszopiclone—GABRA2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	5.59e-06	0.00175	CbGpPWpGaD
Eszopiclone—CYP2C9—Metapathway biotransformation—CYP1B1—ovarian cancer	5.59e-06	0.00175	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	5.57e-06	0.00175	CbGpPWpGaD
Eszopiclone—GABRA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	5.54e-06	0.00174	CbGpPWpGaD
Eszopiclone—GABRA3—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	5.5e-06	0.00172	CbGpPWpGaD
Eszopiclone—GABRA1—SIDS Susceptibility Pathways—CASP3—ovarian cancer	5.47e-06	0.00171	CbGpPWpGaD
Eszopiclone—GABRG2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	5.46e-06	0.00171	CbGpPWpGaD
Eszopiclone—GABRA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	5.44e-06	0.0017	CbGpPWpGaD
Eszopiclone—GABRG3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	5.44e-06	0.0017	CbGpPWpGaD
Eszopiclone—GABRG3—Transmembrane transport of small molecules—ABCB1—ovarian cancer	5.4e-06	0.00169	CbGpPWpGaD
Eszopiclone—GABRA2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	5.4e-06	0.00169	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	5.37e-06	0.00168	CbGpPWpGaD
Eszopiclone—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	5.34e-06	0.00167	CbGpPWpGaD
Eszopiclone—GABRA1—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	5.27e-06	0.00165	CbGpPWpGaD
Eszopiclone—GABRG2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	5.27e-06	0.00165	CbGpPWpGaD
Eszopiclone—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	5.21e-06	0.00163	CbGpPWpGaD
Eszopiclone—GABRG3—Transmission across Chemical Synapses—MAPK1—ovarian cancer	5.09e-06	0.0016	CbGpPWpGaD
Eszopiclone—GABRA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	5e-06	0.00157	CbGpPWpGaD
Eszopiclone—GABRA4—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.97e-06	0.00156	CbGpPWpGaD
Eszopiclone—GABRA1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	4.77e-06	0.00149	CbGpPWpGaD
Eszopiclone—GABRA4—Transmission across Chemical Synapses—MAPK1—ovarian cancer	4.68e-06	0.00147	CbGpPWpGaD
Eszopiclone—GABRA1—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	4.64e-06	0.00146	CbGpPWpGaD
Eszopiclone—GABRA1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	4.61e-06	0.00144	CbGpPWpGaD
Eszopiclone—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	4.58e-06	0.00143	CbGpPWpGaD
Eszopiclone—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	4.56e-06	0.00143	CbGpPWpGaD
Eszopiclone—GABRB2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.55e-06	0.00143	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	4.54e-06	0.00142	CbGpPWpGaD
Eszopiclone—PTGS1—Selenium Micronutrient Network—IL6—ovarian cancer	4.52e-06	0.00142	CbGpPWpGaD
Eszopiclone—GABRA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	4.45e-06	0.00139	CbGpPWpGaD
Eszopiclone—GABRA5—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.42e-06	0.00139	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	4.37e-06	0.00137	CbGpPWpGaD
Eszopiclone—GABRA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	4.36e-06	0.00137	CbGpPWpGaD
Eszopiclone—GABRA3—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.34e-06	0.00136	CbGpPWpGaD
Eszopiclone—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	4.29e-06	0.00134	CbGpPWpGaD
Eszopiclone—GABRB2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	4.28e-06	0.00134	CbGpPWpGaD
Eszopiclone—GABRA2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.26e-06	0.00134	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—NME2—ovarian cancer	4.25e-06	0.00133	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—CYTB—ovarian cancer	4.23e-06	0.00133	CbGpPWpGaD
Eszopiclone—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	4.18e-06	0.00131	CbGpPWpGaD
Eszopiclone—GABRA5—Transmission across Chemical Synapses—MAPK1—ovarian cancer	4.16e-06	0.0013	CbGpPWpGaD
Eszopiclone—GABRG2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.16e-06	0.0013	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.14e-06	0.0013	CbGpPWpGaD
Eszopiclone—GABRA3—Transmission across Chemical Synapses—MAPK1—ovarian cancer	4.09e-06	0.00128	CbGpPWpGaD
Eszopiclone—GABRG3—Transmission across Chemical Synapses—HRAS—ovarian cancer	4.09e-06	0.00128	CbGpPWpGaD
Eszopiclone—GABRA2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	4.02e-06	0.00126	CbGpPWpGaD
Eszopiclone—GABRG2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	3.92e-06	0.00123	CbGpPWpGaD
Eszopiclone—GABRG3—Neuronal System—MAPK1—ovarian cancer	3.9e-06	0.00122	CbGpPWpGaD
Eszopiclone—GABRA4—Transmission across Chemical Synapses—HRAS—ovarian cancer	3.76e-06	0.00118	CbGpPWpGaD
Eszopiclone—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	3.74e-06	0.00117	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—PPP1CC—ovarian cancer	3.7e-06	0.00116	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—BRIP1—ovarian cancer	3.7e-06	0.00116	CbGpPWpGaD
Eszopiclone—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	3.69e-06	0.00116	CbGpPWpGaD
Eszopiclone—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	3.66e-06	0.00115	CbGpPWpGaD
Eszopiclone—GABRA1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	3.64e-06	0.00114	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.6e-06	0.00113	CbGpPWpGaD
Eszopiclone—GABRA4—Neuronal System—MAPK1—ovarian cancer	3.59e-06	0.00113	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—NME2—ovarian cancer	3.45e-06	0.00108	CbGpPWpGaD
Eszopiclone—GABRB2—Transmission across Chemical Synapses—HRAS—ovarian cancer	3.44e-06	0.00108	CbGpPWpGaD
Eszopiclone—GABRA1—Transmission across Chemical Synapses—MAPK1—ovarian cancer	3.43e-06	0.00107	CbGpPWpGaD
Eszopiclone—GABRA5—Transmission across Chemical Synapses—HRAS—ovarian cancer	3.34e-06	0.00105	CbGpPWpGaD
Eszopiclone—GABRB2—Neuronal System—MAPK1—ovarian cancer	3.28e-06	0.00103	CbGpPWpGaD
Eszopiclone—GABRA3—Transmission across Chemical Synapses—HRAS—ovarian cancer	3.28e-06	0.00103	CbGpPWpGaD
Eszopiclone—GABRA2—Transmission across Chemical Synapses—HRAS—ovarian cancer	3.22e-06	0.00101	CbGpPWpGaD
Eszopiclone—GABRA1—SIDS Susceptibility Pathways—IL6—ovarian cancer	3.21e-06	0.00101	CbGpPWpGaD
Eszopiclone—GABRA5—Neuronal System—MAPK1—ovarian cancer	3.19e-06	0.001	CbGpPWpGaD
Eszopiclone—GABRG2—Transmission across Chemical Synapses—HRAS—ovarian cancer	3.15e-06	0.000986	CbGpPWpGaD
Eszopiclone—GABRA3—Neuronal System—MAPK1—ovarian cancer	3.13e-06	0.000982	CbGpPWpGaD
Eszopiclone—GABRG3—Neuronal System—HRAS—ovarian cancer	3.13e-06	0.000981	CbGpPWpGaD
Eszopiclone—GABRA2—Neuronal System—MAPK1—ovarian cancer	3.08e-06	0.000965	CbGpPWpGaD
Eszopiclone—GABRG2—Neuronal System—MAPK1—ovarian cancer	3e-06	0.000941	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.94e-06	0.00092	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	2.93e-06	0.000919	CbGpPWpGaD
Eszopiclone—GABRA4—Neuronal System—HRAS—ovarian cancer	2.88e-06	0.000903	CbGpPWpGaD
Eszopiclone—GABRA1—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.75e-06	0.000862	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—CYTB—ovarian cancer	2.74e-06	0.000857	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.7e-06	0.000845	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.67e-06	0.000838	CbGpPWpGaD
Eszopiclone—GABRB2—Neuronal System—HRAS—ovarian cancer	2.64e-06	0.000826	CbGpPWpGaD
Eszopiclone—GABRA1—Neuronal System—MAPK1—ovarian cancer	2.62e-06	0.000823	CbGpPWpGaD
Eszopiclone—GABRA5—Neuronal System—HRAS—ovarian cancer	2.56e-06	0.000803	CbGpPWpGaD
Eszopiclone—GABRA3—Neuronal System—HRAS—ovarian cancer	2.51e-06	0.000788	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—YAP1—ovarian cancer	2.48e-06	0.000778	CbGpPWpGaD
Eszopiclone—GABRA2—Neuronal System—HRAS—ovarian cancer	2.47e-06	0.000774	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.46e-06	0.00077	CbGpPWpGaD
Eszopiclone—GABRG2—Neuronal System—HRAS—ovarian cancer	2.41e-06	0.000756	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—PPP1CC—ovarian cancer	2.39e-06	0.000749	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—BRIP1—ovarian cancer	2.39e-06	0.000749	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.39e-06	0.000749	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—NME2—ovarian cancer	2.28e-06	0.000714	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—CYTB—ovarian cancer	2.23e-06	0.000698	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.18e-06	0.000682	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.16e-06	0.000677	CbGpPWpGaD
Eszopiclone—GABRA1—Neuronal System—HRAS—ovarian cancer	2.11e-06	0.00066	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—FASN—ovarian cancer	2.02e-06	0.000634	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—SLC5A5—ovarian cancer	1.99e-06	0.000624	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—BRIP1—ovarian cancer	1.95e-06	0.00061	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—PPP1CC—ovarian cancer	1.95e-06	0.00061	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—SLC2A1—ovarian cancer	1.92e-06	0.000603	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.88e-06	0.00059	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—CYP1B1—ovarian cancer	1.84e-06	0.000578	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.74e-06	0.000546	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—PPP2R1A—ovarian cancer	1.63e-06	0.000512	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.63e-06	0.00051	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—YAP1—ovarian cancer	1.6e-06	0.000503	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.59e-06	0.000497	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—ABCB1—ovarian cancer	1.52e-06	0.000476	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—TYMS—ovarian cancer	1.49e-06	0.000467	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—CYTB—ovarian cancer	1.47e-06	0.00046	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.42e-06	0.000444	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.4e-06	0.000437	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—FASN—ovarian cancer	1.31e-06	0.00041	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—YAP1—ovarian cancer	1.31e-06	0.000409	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.29e-06	0.000405	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—SLC5A5—ovarian cancer	1.29e-06	0.000403	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.28e-06	0.000402	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.28e-06	0.000402	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—SLC2A1—ovarian cancer	1.24e-06	0.000389	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.22e-06	0.000381	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—CAV1—ovarian cancer	1.2e-06	0.000377	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—CYP1B1—ovarian cancer	1.19e-06	0.000373	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.15e-06	0.00036	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.14e-06	0.000356	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—PIK3CG—ovarian cancer	1.09e-06	0.000343	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—FASN—ovarian cancer	1.06e-06	0.000333	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	1.06e-06	0.000331	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.05e-06	0.000329	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—SLC5A5—ovarian cancer	1.05e-06	0.000328	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—SLC2A1—ovarian cancer	1.01e-06	0.000317	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	9.9e-07	0.00031	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—ABCB1—ovarian cancer	9.81e-07	0.000307	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—CYP1B1—ovarian cancer	9.69e-07	0.000304	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—TYMS—ovarian cancer	9.63e-07	0.000302	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—PIK3CD—ovarian cancer	9.62e-07	0.000302	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—YAP1—ovarian cancer	8.61e-07	0.00027	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	8.59e-07	0.000269	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	8.55e-07	0.000268	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—PIK3CB—ovarian cancer	8.38e-07	0.000263	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—ABCB1—ovarian cancer	7.98e-07	0.00025	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—TYMS—ovarian cancer	7.84e-07	0.000246	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—CAV1—ovarian cancer	7.76e-07	0.000243	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.41e-07	0.000232	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—PTEN—ovarian cancer	7.25e-07	0.000227	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—PIK3CG—ovarian cancer	7.07e-07	0.000222	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—FASN—ovarian cancer	7.02e-07	0.00022	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—SLC5A5—ovarian cancer	6.9e-07	0.000216	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—SLC2A1—ovarian cancer	6.67e-07	0.000209	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—CYP1B1—ovarian cancer	6.39e-07	0.0002	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—CAV1—ovarian cancer	6.32e-07	0.000198	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—PIK3CD—ovarian cancer	6.21e-07	0.000195	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.03e-07	0.000189	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—PIK3CG—ovarian cancer	5.75e-07	0.00018	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	5.67e-07	0.000178	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—PIK3CB—ovarian cancer	5.42e-07	0.00017	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—ABCB1—ovarian cancer	5.26e-07	0.000165	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—TYMS—ovarian cancer	5.17e-07	0.000162	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—PIK3CA—ovarian cancer	5.11e-07	0.00016	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—PIK3CD—ovarian cancer	5.06e-07	0.000159	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—PTEN—ovarian cancer	4.68e-07	0.000147	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—PIK3CB—ovarian cancer	4.41e-07	0.000138	CbGpPWpGaD
Eszopiclone—PTGS1—Metabolism—AKT1—ovarian cancer	4.18e-07	0.000131	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—CAV1—ovarian cancer	4.17e-07	0.000131	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—PTEN—ovarian cancer	3.81e-07	0.000119	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—PIK3CG—ovarian cancer	3.79e-07	0.000119	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—PIK3CD—ovarian cancer	3.34e-07	0.000105	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—PIK3CA—ovarian cancer	3.3e-07	0.000103	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.91e-07	9.11e-05	CbGpPWpGaD
Eszopiclone—CYP2C8—Metabolism—AKT1—ovarian cancer	2.7e-07	8.45e-05	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—PIK3CA—ovarian cancer	2.69e-07	8.42e-05	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—PTEN—ovarian cancer	2.51e-07	7.87e-05	CbGpPWpGaD
Eszopiclone—CYP2C9—Metabolism—AKT1—ovarian cancer	2.2e-07	6.88e-05	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.77e-07	5.55e-05	CbGpPWpGaD
Eszopiclone—CYP3A4—Metabolism—AKT1—ovarian cancer	1.45e-07	4.54e-05	CbGpPWpGaD
